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Figure 1 Multidetector CT Evaluation Pre-TAVI
Computed tomography (CT) angiographic measurements in the long-axis view for the right (A) and left (B) coronary artery height. The coronary height was measured from the
aortic annulus plane to the lower level margin of the right (A) and left (B) coronary ostia. While maintaining the orientation, the images are scrolled up to allow for short-axis
measurement of the sinus of Valsalva (C) and then down to provide measures of the annulus/basal ring (D). TAVI ¼ transcatheter aortic valve implantation.
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1554event assignment) (9). Also, all centers were asked to provide
data on the entire population undergoing TAVI with no
coronary obstruction in each center; the data included mean
age and logistic EuroSCORE (European System for Cardiac
Operative Risk Evaluation) (logEuroSCORE), and the
percentage of women, and patients with previous coronary
artery disease and previous coronary artery bypass graft
(CABG). The total number of TAVI cases per center, as
well as data on valve type, approach, and valve-in-valve
procedures (cases with a previous surgical aortic bio-
prosthesis) were gathered.
Computed tomography. Data on coronary height, aortic
annulus diameter and area, sinus of Valsalva (SOV) diameter,
diameter of the sinotubular junction, and severity of valve
calciﬁcation (Agatston units) were obtained in those patients
with CT performed prior to the TAVI procedure. CT exams
were evaluated in a central core-lab by 2 investigators (S.P.,
H.B.R.) and all measurements, but valve calciﬁcation severity,
were performed with the CT images obtained following
contrast injection. The techniques used for all these CT
measurements have been described in detail in previousreports (10–12), and are summarized in Figure 1. The CT
measurements from patients with coronary obstruction fol-
lowing TAVI were compared with those obtained in a control
group (no coronary obstruction) of 345 consecutive patients,
obtained from January 2011 to December 2012, in 3 par-
ticipating centers, with both valve types.
Statistical analysis. Categorical variables are reported as
n (%) and continuous variables are expressed as mean  SD
or median (interquartile range [IQR]) depending on variable
distribution. Group comparisons were analyzed using the
Student t test or Wilcoxon rank sum test. The chi-square
test and the Fisher exact test were performed for categor-
ical variables. To further evaluate the CT variables associated
with coronary obstruction, patients with this complication
and without previous surgical bioprosthesis were matched
1:1 with control subjects from a CT cohort of 345 patients
using the bootstrap technique (1,000 samples with replace-
ment). The clinical variables used for the match were age 
2 years, sex, previous CABG, valve type, and size. All
analysis were conducted using the statistical package SAS
(version 9.2, SAS Institute Inc., Cary, North Carolina).
Table 1
Baseline and Procedural Characteristics of the
Patients With Coronary Obstruction Following TAVI
(n ¼ 44)
Clinical variables
Age, yrs 83.1  8.0
Female 37 (84.1)
Body mass index, kg/m2 25.3  6.0
NYHA functional class
I–II 7 (15.9)
III–IV 37 (84.1)
Diabetes 15 (34.1)
Dyslipidemia 25 (56.8)
Hypertension 41 (93.2)
Coronary artery disease 19 (43.2)
Previous myocardial infarction 6 (13.6)
Prior PCI 9 (20.5)
Prior CABG 4 (9.1)
Patent LIMA/graft to LAD 2 (50)
Complete revascularization prior to TAVI 31 (70.5)
Prior aortic valve surgery 3 (6.8)
Previous pacemaker 8 (18.2)
Cerebrovascular disease 9 (20.5)
Peripheral vascular disease 17 (38.6)
COPD 11 (25.0)
Porcelain aorta 3 (6.8)
eGFR, <60 ml/min 23 (52.3)
logEuroSCORE, % 23.2  16.2
Echocardiographic variables
Mean aortic gradient, mm Hg 54.5  17.8
Aortic valve area, cm2 0.53  0.19
LVEF, % 53.5  14.7
Annulus size, mm 20.4  1.5
Procedural variables
Approach
Transfemoral 30 (68.2)
Transapical 13 (29.5)
Transaortic 1 (2.3)
Valve-in-valve 3 (6.8)
Prosthesis size, mm
23 25 (56.8)
26 15 (34.1)
29 3 (6.8)
31 1 (2.3)
Prosthesis type
Balloon-expandable valve: Sapien/Sapien XT 37 (84.1)
Self-expandable valve: CoreValve 7 (15.9)
Balloon pre-dilation 40 (90.9)
Balloon post-dilation 8 (18.2)
Values are mean  SD or n (%). Sapien and Sapien XT are products of Edwards Lifesciences (Irvine,
California); CoreValve is a product of Medtronic (Minneapolis, Minnesota).
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼
estimated glomerular ﬁltration ratio; EuroSCORE ¼ European System for Cardiac Operative Risk
Evaluation; LAD ¼ left anterior descending artery; LIMA ¼ left internal mammary artery;
logEuroSCORE ¼ logistic EuroSCORE predicted risk of mortality; LVEF ¼ left ventricular ejection
fraction; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention; TAVI ¼
transcatheter aortic valve implantation.
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Of 6,688 patients who underwent a TAVI procedure in 81
centers worldwide, 44 cases (0.66%) of acute symptomatic
coronary obstruction occurred following the procedure. The
clinical and procedural characteristics of the study population
are shown in Table 1, and the main clinical and procedural
characteristics of the coronary obstruction cases compared
with the rest of the study population are shown in Table 2.
Patients who suffered symptomatic coronary obstruction were
older and more frequently women (p < 0.001 for both), had
less frequently a history of CABG (p ¼ 0.043), exhibited
a higher risk proﬁle as evaluated by logEuroSCORE (p <
0.001), more frequently had a previous surgical aortic bio-
prosthesis (p ¼ 0.045), and had more frequently received
a balloon-expandable valve (p ¼ 0.023 vs. self-expandable
valve). The incidence of coronary obstruction according to
valve type and the presence of a previous surgical bioprosthesis
(“valve-in-valve procedure”) are shown in Figure 2. The
incidence of coronary obstruction according to the approach is
shown in Figure 3.
Clinical presentation, management, and outcomes. Data
on clinical presentation and management of coronary ob-
struction, and 30-day outcomes are presented in Table 3.
Coronary obstruction occurred at the ostium of the LCA in
most (88.6%) cases and the diagnosis was made by coronary
angiography in all patients but 1 (post-mortem). Coronary
obstruction was related to the displacement of a calciﬁed
native aortic valve leaﬂet toward the coronary ostium in all
patients but 1 (97.7%), who had an aortic valve cusp
shearing and migration into the LCA. Most cases (68.2%)
presented with severe persistent hypotension, and electro-
cardiographic changes, mainly ST-segment elevation and
ventricular arrhythmias, occurred in 56.8% of the patients.
Coronary revascularization was not attempted in 7
patients (15.9%). In 2 patients who received a CoreValve
system (Medtronic, Minneapolis, Minnesota), coronary
obstruction was resolved by snaring and removing the
transcatheter valve toward the ascending aorta. One patient
with partial obstruction of the right coronary artery (RCA)
ostium was managed with medical treatment and no coro-
nary revascularization was attempted. Another 3 patients
died within the few minutes following a complete coronary
obstruction of the LCA, with no time for any coronary
revascularization attempt. PCI was attempted in 33 patients
(75%), and it was successful (residual stenosis <20% and
TIMI [Thrombolysis In Myocardial Infarction] ﬂow grade
3) in 81.8% of them.
Procedural death occurred in 7 patients (15.9%), and
among those patients who survived the procedure, 11
had died at 30 days, leading to a 30-day mortality rate of
40.9%. The causes of death in these patients were sepsis
(n ¼ 6), cardiogenic shock (n ¼ 4), and hypoxic brain injury
(n ¼ 1). The 30-day mortality rate according to the type
and results of coronary revascularization treatment is shown
in Figure 4. Thirty-day survival was 66.7% among patientswho received cardiopulmonary bypass as mechanical
support (without CABG). In patients who survived
the procedure, the median hospitalization length was 6
(IQR: 3 to 17) days, and echocardiographic data showed
Table 2
Main Clinical and Procedural Characteristics, According to the Occurrence
of Coronary Obstruction Following TAVI
Coronary Obstruction
(n ¼ 44)
Control Subjects
(n ¼ 6,644) p Value
Clinical variables
Age, yrs 83.1  8.0 81.0  7.1 <0.001
Female 37 (84.1) 3,408 (51.3) <0.001
Prior CAD 19 (43.2) 2,270 (55.5)* 0.258
Previous CABG 4 (9.1) 919 (22.5)* 0.043
logEuroSCORE, % 23.2  16.2 18.1  13.6 <0.001
Procedural variables
Valve type 0.023
Sapien/Sapien XT 37 (84.1) 4,533 (68.2)
CoreValve 7 (15.9) 2,066 (31.1)
Others d 45 (0.7)
Approach 0.442
Transfemoral 30 (68.2) 4,904 (73.8)
Transapical 13 (29.5) 1,546 (23.3)
Transaortic/trans-subclavian 1 (2.3) 194 (2.9)
Valve-in-valve 3 (6.8) 118 (1.8) 0.045
Values are mean  SD or n (%). The d indicates that there was no case of coronary obstruction with the other valves. Sapien and
Sapien XT are products of Edwards Lifesciences (Irvine, California); CoreValve is a product of Medtronic (Minneapolis, Minnesota). *Data
available for 4,386 patients.
CAD ¼ coronary artery disease; other abbreviations as in Table 1.
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1556a mean residual gradient of 10.9  7.9 mm Hg, and a valve
area of 1.66  0.36 cm2. Residual aortic regurgitation was
absent/trivial, mild, and moderate in 33.4%, 58.3%, and
8.3% of the patients, respectively.
At a median follow-up of 12 (IQR: 2 to 18) months,
20 patients had died (cumulative mortality rate: 45.5%).
Among those patients who survived at 30 days, 2 patients
died during the follow-up period of unknown causes. The
vast majority of patients (95%) were in New York Heart
Association functional class I to II at follow-up. There were
no cases of stent thrombosis or repeat revascularization. TheFigure 2 Incidence of Coronary Obstruction According to Valve Type
Incidence of coronary obstruction following transcatheter aortic valve implantation with s
aortic valves.Kaplan-Meier survival curves at 1-year follow-up are shown
in Figure 5.
CT data. Pre-TAVI CT data were available in 28 of 44
patients with coronary obstruction (63.6%). CT data of the
patients with coronary obstruction compared with those of
the control group are shown in Table 4. The main clinical
characteristics of the CT control group were similar to the
overall study population with no coronary obstruction fol-
lowing TAVI (Online Table 1). Patients with coronary ob-
struction exhibited a smaller aortic annulus area (p ¼ 0.002),
SOV diameter (p< 0.001), and sinotubular junction diameterand Valve-In-Valve Procedures
elf-expandable or balloon-expandable valves, as well as in native or prosthetic
Figure 3
Incidence of Coronary Obstruction According to the
Different Approaches for TAVI
Incidence of coronary obstruction following transcatheter aortic valve implantation
(TAVI) through the transfemoral, transapical, and transaortic/trans-subclavian
approaches.
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1557(p ¼ 0.003), as well as a lower LCA height (p < 0.001). As
women represented the vast majority of patients in the coro-
nary obstruction group, a separate analysis of the CT data
in women only was also performed (Online Table 2).
The results of the case-matched analysis including 27
patients without previous surgical bioprosthesis in both
groups are shown in Table 5. The SOV diameter remained
smaller in the coronary obstruction group (odds ratio
[OR]: 1.37; 95% conﬁdence interval [CI]: 1.13 to 1.66)
and LCA height lower as compared with that of control
subjects (OR: 2.17; 95% CI: 1.62 to 2.90). The individual
data for LCA height and SOV diameters are shown in
Figure 6. Up to 86% of the patients who had a coronary
obstruction had a LCA height of <12 mm, compared with
26.4% of the patients in the control group (p < 0.001). The
SOV diameter was <30 mm in 71.4% of the patients who
had coronary obstruction compared with 33% of the
patients in the control group (p < 0.001). Most patients
(67.9%) who had coronary obstruction had both a LCA
height <12 mm and a SOV diameter <30 mm compared
with 13.3% of the patients in the control group (p< 0.001).Discussion
Coronary obstruction and TAVI: incidence and associated
factors. Potential concerns about the occurrence of coronary
obstruction had been pointed out in the very ﬁrst experi-
mental models evaluating the TAVI technique (13,14), and
the occurrence of this complication was also reported in the
ﬁrst human experiences of TAVI (15). The incidence of this
complication in subsequent large TAVI series and registries
has been low, nearly systematically lower than 1% (1–7,16).
The results of the present study, with a systematic evaluation
of this complication in a multicenter cohort including >6,500
TAVI procedures, conﬁrmed an incidence of coronary
obstruction of <1% (0.66%).Whereas the incidence of this complication was low for
the 2 transcatheter valve types (balloon-expandable and self-
expandable), the coronary obstruction rate was as much
as twice as high among patients who received a balloon-
expandable valve (0.81% vs. 0.34% among those who re-
ceived a self-expandable valve). A recent review of TAVI
complications including all TAVI studies with 100
patients also found a tendency toward a higher incidence of
coronary obstruction in patients treated with a balloon-
expandable valve (1.1%) compared with those treated with
a self-expandable valve (0.4%) (16). This is also consistent
with the systematic review of the reported cases of coronary
obstruction to date, which involved a balloon-expandable
valve in >80% of the cases (8). Differences in both the
frame characteristics of the 2 transcatheter valve systems
(straight stainless steel or cobalt chromium vs. nitinol with a
concave shape at the level of coronary arteries) and the
mechanisms for valve implantation (balloon-expandable vs.
self-expandable) might partially explain these differences.
However, the speciﬁc recommendations on SOV diameter
and coronary ostia height for the CoreValve system im-
plantation could also have played a role in these differences.
In fact, whereas no speciﬁc formal recommendation for SOV
width and coronary ostia height was provided for the
implantation of the Edwards valve (Edwards Lifesciences,
Irvine, California), a recommendation of a SOV width
of 27 mm (for the 26-mm CoreValve) or 28 mm (for
the 29-mm CoreValve) and a coronary height of 14 mm
was provided by the manufacturer for the implantation of the
CoreValve system. Although these speciﬁc recommendations
might not have been followed by all CoreValve implanting
centers, it may possibly have prevented a signiﬁcant number
of coronary obstructions with the CoreValve system.
The occurrence of coronary obstruction was also more
frequent among patients with previous surgical aortic bio-
prosthesis (“valve-in-valve” procedures). The incidence of
coronary obstruction of 2.4% in such patients was close to the
3.5% rate reported in a recent multicenter registry of valve-
in-valve TAVI procedures (17). Some types of surgical
aortic bioprosthesis such as stentless valves or stented valves
with long leaﬂets have been associated with this complica-
tion, and future studies with a much larger number of patients
will be needed to further evaluate the factors associated with
coronary obstruction in this speciﬁc group of patients.
Whereas women represent about 50% of the patients
treated with TAVI, the vast majority (>80%) of patients
who had coronary obstruction following TAVI were
women. This was consistent with previous data from re-
ported cases of coronary obstruction as a complication of
TAVI, mainly single case reports or small case series, which
involved women in 83% of the cases (8). The association
between female sex and coronary obstruction may be due to
anatomic differences in aortic SOV dimensions and coro-
nary height according to sex. Previous CT studies have
already shown the smaller aortic SOV dimensions and
lower coronary ostia takeoff in women, irrespective of the
Table 3
Clinical Presentation and Management of
Coronary Obstruction Following TAVI (n ¼ 44)
Obstructed coronary artery
Left coronary artery 39 (88.6)
Right coronary artery 2 (4.5)
Both 3 (6.8)
Timing
After balloon valvuloplasty 4 (9.1)
After valve implantation 31 (70.5)
After balloon post-dilation 4 (9.1)
Within 24 h following TAVI 4 (9.1)
More than 24 h following TAVI 1 (2.3)
Clinical presentation
Severe persistent hypotension 30 (68.2)
ECG changes 25 (56.8)
ST-segment elevation 14 (56.0)
Ventricular ﬁbrillation 7 (28.0)
Ventricular tachycardia 3 (12.0)
Atrial ﬁbrillation 2 (8.0)
Left bundle branch block 2 (8.0)
Stenosis severity
Partial occlusion 25 (56.8)
Complete occlusion 19 (43.2)
Treatment
PCI attempted 33 (75.0)
Successful 27 (81.8)
Stent successfully implanted 25 (75.8)
Guidewire protection only 1 (3.0)
Catheter cannulation only 1 (3.0)
Unsuccessful 6 (18.2)
Coronary cannulation failure 2 (33.3)
Wire crossing failure 2 (33.3)
Stent could not be advanced 1 (16.7)
Stent implanted but no ﬂow 1 (16.7)
Type of stent
Bare-metal stent(s) 6 (24.0)
Drug-eluting stent(s) 17 (68.0)
Bare-metal and drug-eluting stents 2 (8.0)
Urgent CABG 6 (13.6)
Conversion to open heart surgery 2 (6.1)
Continued in the next column
Table 3 Continued
Procedural complications
Need for cardiopulmonary resuscitation 18 (40.9)
Need for hemodynamic support 16 (36.4)
CPB 7 (43.8)
IABP 4 (25.0)
Fem-Fem CPB 3 (18.8)
ECMO 1 (6.3)
Impella 1 (6.3)
Inotropes 30 (68.2)
Valve embolization 2 (4.5)
Need for a second valve 3 (6.8)
Cardiac tamponade 3 (6.8)
30-day outcomes
Myocardial infarction 21 (47.7)
Peak CK-MB, mg/l 82.4 (24.3–240.6)
New Q waves* 5 (35.7)
New left bundle branch block 4 (9.1)
New pacemaker 1 (2.3)
Major vascular complications 5 (11.4)
Major or life-threatening bleeding 7 (15.9)
Acute renal failure 9 (20.4)
Dialysis 2 (4.5)
Stroke 4 (9.1)
Death 18 (40.9)
Hospitalization length, days 6 (3–17)
Values are n (%) ormedian (interquartile range). *After excluding the patients with procedural death.
CK-MB ¼ creatine kinase-myocardial band; CPB ¼ cardiopulmonary bypass; ECG ¼ electrocar-
diographic; ECMO ¼ extracorporeal membrane oxygenation; Fem-Fem ¼ femoral-femoral bypass;
IABP ¼ intra-aortic balloon pump; other abbreviations as in Table 1.
Figure 4
Mortality Rate at 30 Days According to the Type and
Results of the Treatment for Coronary Obstruction
Mortality at 30 days following successful percutaneous coronary intervention (PCI),
unsuccessful PCI, or coronary artery bypass graft (CABG) after the occurrence of
coronary obstruction.
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1558presence of aortic stenosis (11,18), and these sex differences
in aortic SOV dimensions and coronary height were also
observed in the pre-TAVI CT exams of our control group
including >300 patients (33.8  3.9 mm vs. 29.7  3.1
mm for SOV dimensions; 14.1  2.1 mm vs. 12.7  1.8
mm for LCA coronary height in men and women,
respectively; p < 0.001 for both). It has been shown that
coronary obstruction following TAVI is mainly due to the
displacement of the calciﬁed native cusp over the coronary
ostia, and this was also the mechanism of coronary
obstruction in 98% of the patients in the present study.
Therefore, it is not surprising that aortic SOV dimensions
and coronary height were shown to be important factors
associated with the occurrence of coronary obstruction
following TAVI in this study. Patients with coronary
obstruction exhibited a lower coronary ostia takeoff of theLCA. The mean LCA height in patients with coronary
obstruction was of about 11 mm (10 mm in women), as
compared with about 13 mm in those patients without
coronary obstruction. Importantly, most patients who
Figure 5 Kaplan-Meier Survival Curves at 1-Year Follow-Up
Survival curve showing a mortality rate of 45.5% at 1-year follow-up after trans-
catheter aortic valve implantation complicated with coronary obstruction.
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1559suffered coronary obstruction (about 80% overall, 96% of
the women) had a LCA height of <12 mm, suggesting that
this may be a more accurate cutoff than the 10-mm cutoff
suggested by the American College of Cardiology Foun-
dation/American Association for Thoracic Surgery/Society
for Cardiovascular Angiography and Interventions/Society
of Thoracic Surgeons and the CT-TAVI expert consensus
(10,19), and the 14-mm cutoff suggested by the manu-
facturer regarding the CoreValve implantation. Moreover,
the 12-mm cutoff would be in the upper limit of the 95%
CI from the coronary obstruction cases and would not be
included in the lower limit for the control subjects. The
RCA ostia takeoff is usually higher than that of the LCA
(11,12), and this is probably the reason why RCA
obstruction after TAVI is very infrequent (only 11% of the
cases in the present series). Whereas the RCA ostia heightTable 4
Computed Tomography Data, According t
Following TAVI
Coronary Obstruc
(n ¼ 28)
Annulus diameter, mm 22.9  3.1
Annulus area, mm2 387 (375–424
Aortic SOV diameter, mm 28.1  3.8
Sinotubular junction, mm 25.2  3.1
Relation prosthesis size/annulus 1.09  0.11
Relation SOV/annulus 1.25  0.17
Left coronary height, mm 10.6  2.1
Right coronary height, mm 12.4  3.2
Left coronary height, mm* 10.4  2.0
Right coronary height, mmy 11.3  2.1
Calcium score, Agatston units 2,354  1,187
Values are mean  SD or median (interquartile range). *Cases of right corona
excluded.
SOV ¼ sinus of Valsalva; other abbreviations as in Tables 1 and 3.was also found to be lower in patients who had RCA
obstruction after TAVI, the low number of patients
with this complication precluded drawing any reliable
conclusions about the RCA cutoff height associated with
an increased risk.
Although coronary ostia height is an important factor
associated with coronary obstruction following TAVI, a
signiﬁcant number of patients in the coronary obstruction
group suffered this complication despite a LCA coronary
height of >12 mm (21.4%), indicating that factors other
than coronary height are also involved in this complication.
A narrow aortic root leaving little room to accommodate
the native aortic leaﬂets may also contribute to coronary
obstruction after TAVI. In fact, coronary obstruction was
associated with a certain degree of aortic root effacement as
compared with that of the control group. Most patients
(64.3%) who suffered this complication had an aortic
SOV diameter of <30 mm, as compared with about one-
third of the patients in the control group. In fact, only
a minority of the patients who did not suffer coronary ob-
struction had both, a coronary height of <12 mm and an
aortic SOV diameter of <30 mm (13.3%), meaning that the
combination of these 2 anatomic factors has to be taken into
account when evaluating the possibility of coronary ob-
struction due to TAVI. The degree of valve calciﬁcation as
a global measure was not associated with the occurrence of
coronary obstruction in this study, suggesting that this is
probably not the main anatomic factor associated with post-
TAVI coronary obstruction. However, the presence of bulky
calcium nodules was not speciﬁcally evaluated, and its role in
the occurrence of some cases of coronary obstruction cannot
be ruled out.
In those patients considered at high risk for coronary
obstruction, we would suggest to implement additional se-
curity measures during the TAVI procedure such as simulta-
neous angiography during balloon valvuloplasty to depict
coronary obstruction or coronary protection with a guidewireo the Occurrence of Coronary Obstruction
tion Control Subjects
(n ¼ 345) p Value
24.4  2.9 0.010
) 476 (405–560) 0.002
31.9  4.1 <0.001
28.0  3.9 0.003
1.05  0.09 0.084
1.31  0.14 0.054
13.4  2.1 <0.001
14.1  2.4 0.003
13.5  2.0 <0.001
14.0  2.4 0.048
2,872  1,726 0.290
ry artery obstruction excluded. yCases of left coronary artery obstruction
Table 5
CT Data From the Case-Matched Analysis, According to the Occurrence of
Coronary Obstruction Following TAVI
Coronary Obstruction
(n ¼ 27)
Control Subjects
(n ¼ 27) OR (95% CI) p Value
Annulus diameter, mm 23.0  0.6 23.6  0.4 1.15 (0.92–1.45) 0.510
Annulus area, mm2 410  18 458  17 1.01 (0.99–1.02) 0.126
Aortic SOV diameter, mm 28.3  0.8 31.3  0.6 1.37 (1.13–1.66) 0.011
Relation prosthesis size/annulus 1.08  0.02 1.05  0.02 0.02 (0.01–3.99) 0.315
Relation SOV/annulus 1.26  0.04 1.34  0.03 20.0 (1.28–333) 0.003
Left coronary height, mm 10.7  0.4 13.3  0.3 2.17 (1.62–2.90) <0.001
Right coronary height, mm 12.7  0.8 14.2  0.4 1.36 (1.10–1.68) 0.047
Calcium score, Agatston units 2,284  318 2,733  313 1.00 (0.99–1.10) 0.333
Values are mean  SE.
CI ¼ conﬁdence interval; CT ¼ computed tomography; OR ¼ odd ratio; other abbreviations as in Tables 1 and 4.
Figure 6
Individual Data for the LCA Height and Aortic SOV Diameter According to the Occurrence of Coronary Obstruction
Overall and in Women Only
Individual data on computed tomography from the patients with coronary obstruction and control subjects showing that up to 86% of the patients with coronary obstruction
had a left coronary artery (LCA) height of <12 mm, compared with 26% of the patients in the control group (A). In women, up to 96% of the patients with coronary
obstruction group had an LCA <12 mm compared with 36% in the control group (B). The sinus of Valsalva (SOV) diameter was <30 mm in 71% of the patients who had coronary
obstruction versus 33% in the control subjects (C). In women, up to 78% of the patients in the coronary obstruction group had an SOV <30 mm versus 55% in the control
group (D).
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1561in the presence of clinical and anatomical parameters of risk.
Finally, the use of a transcatheter valve that can be repositio-
ned or retrieved in case of coronary obstruction following valve
implantation should probably be recommended in such cases.
Coronary obstruction following TAVI: management and
clinical outcomes. Most of the patients with coronary
obstruction presented with persistent severe hypotension,
about one-half of them exhibited electrocardiographic
changes, mainly ST-segment elevation, and more than one-
third had ventricular arrhythmias. These data suggest that
in case of persistent hypotension following valve implanta-
tion, coronary obstruction should be included in the differ-
ential diagnosis irrespective of electrocardiographic changes,
and prompt echocardiography to detect new segmental
abnormalities and/or coronary angiography to detect coro-
nary obstruction should be performed.
The present study also showed that PCI was the preferred
strategy for the treatment of coronary obstruction following
TAVI. Importantly, PCI was feasible (attempted in 75% of
the patients) and had a success rate of 81.8%. Still, urgent
CABG or mechanical hemodynamic support (mainly car-
diopulmonary bypass) were needed in 14% and 36% of the
patients, respectively, underscoring the importance of per-
forming these procedures in highly experienced centers with
cardiac surgery facilities. These results differ from those of
a recent systematic review of the literature that included
small case series and case reports, where PCI was attempted
in 96% of the patients and was successful in 91% of them
(8). In fact, the reported patients might have tended to
pursue a better outcome than those who were not published
(“selection bias”). This is also supported by the fact that
our 30-day death rate was as high as 41%, as compared
with <10% in the systematic review of reported cases (8).
The mortality rate was high after successful PCI (22%) or
CABG (50%) and increased to as much as 100% in case of
unsuccessful PCI. Whereas these results suggest that PCI as
a ﬁrst attempt for coronary revascularization is a reasonable
strategy, it also highlights the importance of both obtaining
coronary ﬂow restoration very rapidly and being ready to
change the therapeutic strategy (cardiopulmonary bypass,
CABG) if coronary ﬂow is not restored within a few minutes
of the attempted PCI.
Study limitations. Only cases with symptomatic coronary
obstruction were gathered; there might have been cases with
previous CABG in which coronary obstruction occurred
without clinical symptoms (“graft protection”). Available
data from baseline clinical characteristics in the global
cohort of TAVI patients were limited to a few clinical
variables and logEuroSCORE. Reporting of cases of
coronary obstruction cases was done on a voluntary basis,
and there was no external monitoring done to verify the
accuracy of the data reported by each center. CT data were
available in about two-thirds of the coronary obstruction
patients and in a control group of 345 patients. Although
this was a small control group as compared with the entire
TAVI study population, it still represents 1 of the largestseries with pre-TAVI CT data to date (8,11,12,20–22).
Also, the main clinical characteristics of the control group
were similar to the rest of the study population, and both
LCA height and SOV diameter remained as associated
factors with coronary obstruction after performing a case-
matched comparison. Coronary angiograms leading to the
diagnosis of coronary obstruction were analyzed by the
investigators of each center, with no centralized analyses.
Although the present study represents a large series of
coronary obstruction cases following TAVI, the relatively
low number of events and CT exams precluded the per-
formance of a multivariate analysis to evaluate the in-
dependent predictors of coronary obstruction in this
population. Future prospective studies with a very large
number of patients with systematic CT measurements will
be needed to conﬁrm these results.
Conclusions
The present study, which included the largest series of
patients with coronary obstruction following TAVI to date,
conﬁrmed that this is a rare but life-threatening complica-
tion of TAVI that occurred more frequently in women, in
patients receiving a balloon-expandable valve, and in those
with a previous surgical bioprosthesis. Lower-lying coronary
ostium (<12 mm) and shallow SOV (<30 mm) were related
anatomic factors, and despite successful treatment (mainly
PCI), in most cases, periprocedural mortality remained very
high, which highlights the importance of anticipating and
preventing the occurrence of this complication.
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